Regulus Therapeutics Inc. (RGLS)
NASDAQ: RGLS · IEX Real-Time Price · USD
2.130
-0.090 (-4.05%)
Apr 19, 2024, 12:46 PM EDT - Market open
Company Description
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States.
Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.
The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies.
Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Regulus Therapeutics Inc.
| Country | United States |
| Founded | 2007 |
| IPO Date | Oct 4, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 30 |
| CEO | Joseph P. Hagan M.B.A. |
Contact Details
Address: 4224 Campus Point Court, Suite 210 San Diego, California 92121 United States | |
| Phone | 858-202-6300 |
| Website | regulusrx.com |
Stock Details
| Ticker Symbol | RGLS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001505512 |
| CUSIP Number | 75915K309 |
| ISIN Number | US75915K3095 |
| Employer ID | 26-4738379 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph P. Hagan M.B.A. | Chief Executive Officer and Director |
| Crispina Calsada CPA | Chief Financial Officer |
| Christopher Ray Aker J.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Dr. Preston S. Klassen M.D., M.H.S. | President, Head of Research and Development and Director |
| Daniel J. Penksa | Vice President of Finance and Controller |
| Dr. Claire Susan Padgett M.S., M.T., Ph.D. | Senior Vice President of Clinical Operations |
| Dr. Rekha Garg M.D., M.S. | Senior Vice President of Clinical Development and Regulatory |
| Edmund Lee Ph.D. | Vice President of Translational Medicine |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Apr 9, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 25, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 21, 2024 | 10-K | Annual Report |
| Mar 21, 2024 | 8-K | Current Report |
| Mar 20, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 18, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 14, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |